Trial Profile

Phase I study of AMY109 in combination with antineoplastic drugs in patients with advanced solid tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AMY 109 (Primary) ; Atezolizumab (Primary)
Indications Breast cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Uterine cancer
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Sponsors Chugai Pharmaceutical

Most Recent Events

24 Oct 2023 Results (n=38) presented at the 48th European Society for Medical Oncology Congress
01 Nov 2022 Planned End Date changed from 31 Jan 2023 to 31 Jan 2024.
01 Nov 2022 Planned initiation date changed from 1 Dec 2019 to 1 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com